Teva Pharmaceutical Industries Limited
HealthcareNYSE:TEVA · New York Stock Exchange
+$0.07 today
Vol 4.51M · Avg 6.41M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$17.3B of revenue converted into $1.6B of net income for the selected period. Gross margin is 51.9% and net margin is 9.0%, showing how much revenue survives after costs and taxes. EPS is $1.33, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.3B +4.3% | $16.5B +4.4% | $15.8B +6.2% | $14.9B -6.0% | $15.9B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $8.3B -1.9% | $8.5B +3.4% | $8.2B +3.1% | $8.0B -4.0% | $8.3B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $8.9B +10.9% | $8.1B +5.5% | $7.6B +9.6% | $7.0B -8.2% | $7.6B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 51.8% +3.1pp | 48.7% +0.5pp | 48.2% +1.5pp | 46.7% -1.1pp | 47.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.0B -4.0% | $1.1B +10.7% | $953.0M +13.7% | $838.0M -23.4% | $1.1B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $4.0B +7.3% | $3.7B +5.8% | $3.5B +1.5% | $3.4B -2.4% | $3.5B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $6.8B -19.0% | $8.4B +16.0% | $7.2B -21.4% | $9.2B +56.0% | $5.9B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.0B -5.4% | $1.1B -8.2% | $1.2B -11.9% | $1.3B -1.7% | $1.3B | $374.2M | $1.2B | $631.8M |
| EBITDA | $3.1B -29.1% | $4.4B +184.4% | $1.6B +268.4% | -$925.0M -121.0% | $4.4B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 18.2% -8.6pp | 26.8% +17.0pp | 9.8% +16.0pp | -6.2% -34.0pp | 27.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $2.2B +811.9% | -$303.0M -170.0% | $433.0M +119.7% | -$2.2B -228.0% | $1.7B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 12.5% +14.3pp | -1.8% -4.6pp | 2.7% +17.5pp | -14.7% -25.5pp | 10.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 -100.0% | $68.0M | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $916.0M -2.7% | $941.0M -8.6% | $1.0B +10.6% | $930.0M +4.4% | $891.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$919.0M +6.2% | -$980.0M +7.1% | -$1.1B -11.6% | -$945.0M +9.9% | -$1.0B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.2B +196.5% | -$1.3B -106.3% | -$622.0M +80.2% | -$3.1B -571.1% | $667.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 7.2% +14.9pp | -7.8% -3.8pp | -3.9% +17.1pp | -21.1% -25.3pp | 4.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$180.0M -126.6% | $676.0M +9757.1% | -$7.0M +98.9% | -$643.0M -404.7% | $211.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.4B +186.0% | -$1.6B -193.2% | -$559.0M +77.1% | -$2.4B -686.6% | $417.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | 8.2% +18.1pp | -9.9% -6.4pp | -3.5% +12.9pp | -16.4% -19.0pp | 2.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +184.8% | -$1 -190.0% | -$1 +77.3% | -$2 -678.9% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +182.8% | -$1 -190.0% | -$1 +77.3% | -$2 -678.9% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.1B +1.6% | $1.1B +1.1% | $1.1B +0.8% | $1.1B +0.7% | $1.1B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.2B +3.7% | $1.1B +1.1% | $1.1B +0.8% | $1.1B +0.3% | $1.1B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Natera, Inc.
NASDAQ:NTRA
$30.37B
Biogen Inc.
NASDAQ:BIIB
$29.53B
DexCom, Inc.
NASDAQ:DXCM
$29.08B
Koninklijke Philips N.V.
NYSE:PHG
$25.70B
Waters Corporation
NYSE:WAT
$23.17B
BioNTech SE
NASDAQ:BNTX
$22.90B
Labcorp Holdings Inc.
NYSE:LH
$21.83B
STERIS plc
NYSE:STE
$20.26B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.06B
Insulet Corporation
NASDAQ:PODD
$10.37B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TEVA generate?
Teva Pharmaceutical Industries Limited (TEVA) reported $17.26B of revenue in fiscal 2025.
Is TEVA profitable?
Teva Pharmaceutical Industries Limited (TEVA) reported $1.41B of net income, with a net margin of 8.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.